Identifying Mitochondrial Transcription Factor A As a Potential Biomarker for the Carcinogenesis and Prognosis of Prostate Cancer
Genetic Testing and Molecular Biomarkers · 2023
DOI: 10.1089/gtmb.2022.0141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetic Testing and Molecular Biomarkers, 2023. Verfasst von Yaqiong Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Third Central Hospital of Tianjin, Tianjin, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Mitochondrial functional transformation contributes to the carcinogenesis of the prostate by meeting the metabolic needs of cancer cells. Mitochondrial transcription factor A (TFAM) is a pivotal regulator that maintains homeostasis of mitochondrial function. However, its role in prostate carcinogenesis has not been well elucidated. Materials and Methods: In the present study, we analyzed the expression of TFAM in normal prostate tissue and prostate cancer using public databases; a prostate-tissue chip was used to verify the results. The expression of TFAM in normal cells and in prostate cancer cells was determined by western blotting analysis. We knocked down TFAM in the prostate cancer cell line PC3 using a specific shRNA to explore the potential effects of TFAM in prostatic carcinogenesis.
Results
We observed higher expression levels of TFAM in prostate cancer tissue than in normal prostate tissue and tumor adjacent normal tissues. A receiver operating characteristic curve was drawn that demonstrated the diagnostic efficacy of using TFAM expression for prostate cancer prognoses. Elevated levels of TFAM may indicate poorer overall survival in prostate cancer patients. Western blotting assays also showed that relative to the normal prostatic epithelial cell line RWPE-1, prostate cancer cell lines PC3 and DU145 expressed more TFAM protein. Furthermore, knockdown of TFAM inhibited the colony-formation capability of PC3 cells.
Conclusion
Collectively, these results suggest that TFAM promotes carcinogenesis of the prostate, and may constitute a marker to be used in the diagnosis and prognosis of prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third Central Hospital of Tianjin, Tianjin, China.
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China.
- Artificial Cell Engineering Technology Research Center, Tianjin, China.
ORCID-Profile: Yaqiong Tian
Zitieren
APA
Tian, Y., Fan, Z., Liu, S., Wu, Y., & Liu, S. (2023). Identifying Mitochondrial Transcription Factor A As a Potential Biomarker for the Carcinogenesis and Prognosis of Prostate Cancer. Genetic Testing and Molecular Biomarkers. https://doi.org/10.1089/gtmb.2022.0141
Vancouver
Tian Y, Fan Z, Liu S, Wu Y, Liu S. Identifying Mitochondrial Transcription Factor A As a Potential Biomarker for the Carcinogenesis and Prognosis of Prostate Cancer. Genetic Testing and Molecular Biomarkers. 2023. doi:10.1089/gtmb.2022.0141
BibTeX
@article{Tian2023,
author = {Tian, Yaqiong and Fan, Zhijuan and Liu, Shuang and Wu, Yujing and Liu, Shuye},
title = {Identifying Mitochondrial Transcription Factor A As a Potential Biomarker for the Carcinogenesis and Prognosis of Prostate Cancer},
journal = {Genetic Testing and Molecular Biomarkers},
year = {2023},
doi = {10.1089/gtmb.2022.0141}
}
EUVIMED